(NASDAQ:REPL) SAN FRANCISCO, Sept. 3, 2025 /PRNewswire/ -- Replimune Group Inc. (NASDAQ: REPL) is under fire from investors following a dramatic regulatory setback that sent its stock into freefall. A newly filed securities class action accuses the biotech firm and its leadership of concealing critical...
Related Questions
How will the lawsuit and FDA rejection affect REPL's short‑term share price and volatility?
What are the potential financial liabilities or settlement costs associated with the securities class action?
Will this regulatory setback impact REPL's pipeline timelines and its ability to raise capital or partner with larger pharma companies?